Literature DB >> 6143278

Problems in in vitro receptor binding studies and identification and role of serotonin receptor sites.

J Leysen.   

Abstract

The principles and problems in neurotransmitter receptor radioligand binding studies are discussed. Various types of ligand-membrane interactions are described and criteria and ways for identification of specific receptor binding sites are evaluated. It is questioned whether the endogenous neurotransmitters must have binding affinities of nanomolar order for their receptor sites. The relationship between the numbers of receptor binding sites and functional activity of the receptors is investigated. Serotonin-S1 binding sites are sites labelled at nanomolar concentrations by [3H]serotonin. Various alleged roles for these sites are considered and found to be insufficiently substantiated. Therefore these sites should not yet be regarded as receptor sites. Serotonin-S2 binding sites are sites labelled by potent serotonin antagonists. The sites show a typical distribution in the mammalian brain and are present on blood platelets. The neuronal localization of the sites, investigated by lesion studies is discussed. Serotonin-S2 sites have a role in serotonin-induced behavioural excitation in laboratory animals. A presumed role for the sites in depression and anxiety is to be investigated. Serotonin-S2 sites were also shown to mediate serotonin-induced vasoconstriction and platelet aggregation. The sites were hypothesized from pharmacological and electrophysiological studies. Appropriate tools are lacking for a clear characterization of the multiple sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143278     DOI: 10.1016/0028-3908(84)90066-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

Review 1.  Antidepressants and serotonergic neurotransmission: an integrative review.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

2.  Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.

Authors:  A Doble; D Girdlestone; O Piot; D Allam; J Betschart; A Boireau; A Dupuy; C Guérémy; J Ménager; J L Zundel
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  An inhibitory prejunctional 5-HT1-like receptor in the isolated perfused rat kidney. Apparent distinction from the 5-HT1A, 5-HT1B and 5-HT1C subtypes.

Authors:  K G Charlton; R A Bond; D E Clarke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

4.  Differentiation of pre- and post-synaptic high affinity serotonin receptor binding sites using physico-chemical parameters and modifying agents.

Authors:  M D Hall; H Gozlan; M B Emerit; S el Mestikawy; L Pichat; M Hamon
Journal:  Neurochem Res       Date:  1986-06       Impact factor: 3.996

5.  Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors.

Authors:  P Mazzola-Pomietto; C S Aulakh; K M Wozniak; J L Hill; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  Modulation of serotonin binding sites in the brain of the Djungarian hamster, Phodopus sungorus, during adaptation to a short photoperiod.

Authors:  D Kaminski; N Weiner; G Sturm; W Wesemann
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 7.  Embryonal central neuroepithelial tumors: current concepts and future challenges.

Authors:  S R Vandenberg; M M Herman; L J Rubinstein
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

8.  Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments.

Authors:  K M Wozniak; C S Aulakh; J L Hill; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

9.  3H-TVX Q 7821: identification of 5-HT1 binding sites as target for a novel putative anxiolytic.

Authors:  W U Dompert; T Glaser; J Traber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

10.  Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.

Authors:  L Ugedo; J Grenhoff; T H Svensson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.